Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Desmoid Tumors or Aggressive Fibromatosis
NCT02066181Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2014
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of sorafenib in desmoid fibromatosis (DF), sponsored by National Cancer Institute. Started Mar 2014; status: completed.
02
Drugs
sorafenib
03
Conditions
desmoid fibromatosis (DF)
Beyond the preview
Go deeper on NCT02066181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066181.